The economic evaluation of personalised oncology medicines: ethical challenges

被引：15
作者：
Lewis, Jan R. R. [1 ]
Lipworth, Wendy L. [2 ]
Kerridge, Ian H. [1 ]
Day, Richard O. [3 ]
机构：
[1] Univ Sydney, Ctr Values Eth & Law Med, Sydney, NSW 2006, Australia
[2] Univ New S Wales, Australian Inst Hlth Innovat, Sydney, NSW, Australia
[3] St Vincents Hosp, Sydney, NSW 2010, Australia
来源：
MEDICAL JOURNAL OF AUSTRALIA | 2013年 / 199卷 / 07期
关键词：
CELL LUNG-CANCER; 1ST-LINE TREATMENT; EGFR MUTATION; CARBOPLATIN-PACLITAXEL; OPEN-LABEL; GEFITINIB; SURVIVAL; TRIAL; CHEMOTHERAPY; MULTICENTER;
D O I：
10.5694/mja13.10046
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Insights into the molecular drivers of cancer are providing opportunities for the development of new targeted treatments and more personalised approaches to cancer management Drugs targeting mutant epidermal growth factor receptors, such as erlotinib and gefitinib, may provide more effective, safer and better tolerated treatment options compared with chemotherapy among appropriately selected patients with advanced non-small cell Lung cancer (NSCLC). First-line access to these newer treatments remains unfunded after several considerations by the Pharmaceutical Benefits Advisory Committee and their assessment that these are not cost-effective treatments. We suggest that there may be evidentiary and ethical challenges associated with the assessment of the cost-effectiveness of personalised oncology medicines in Australia, and that a new approach is needed to determine the value and cost-effectiveness of personalised medicine.
引用
收藏
页码：471 / 473
页数：3
相关论文
共 24 条
  • [1] [Anonymous], J CLIN ONCOL S
  • [2] Australian Government Department of Health and Ageing, 2012, PHARM BEN ADV COMM M
  • [3] A cost-effectiveness approach to drug subsidy and pricing in Australia
    Birkett, DJ
    Mitchell, AS
    McManus, P
    [J]. HEALTH AFFAIRS, 2001, 20 (03) : 104 - 114
  • [4] Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non-Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial
    Douillard, Jean-Yves
    Shepherd, Frances A.
    Hirsh, Vera
    Mok, Tony
    Socinski, Mark A.
    Gervais, Radj
    Liao, Mei-Lin
    Bischoff, Helge
    Reck, Martin
    Sellers, Mark V.
    Watkins, Claire L.
    Speake, Georgina
    Armour, Alison A.
    Kim, Edward S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (05) : 744 - 752
  • [5] Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence
    Gridelli, C.
    De Marinis, F.
    Di Maio, M.
    Cortinovis, D.
    Cappuzzo, F.
    Mok, T.
    [J]. LUNG CANCER, 2011, 71 (03) : 249 - 257
  • [6] First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
    Han, Ji-Youn
    Park, Keunchil
    Kim, Sang-We
    Lee, Dae Ho
    Kim, Hyae Young
    Kim, Heung Tae
    Ahn, Myung Ju
    Yun, Tak
    Ahn, Jin Seok
    Suh, Cheolwon
    Lee, Jung-Shin
    Yoon, Sung Jin
    Han, Jong Hee
    Lee, Jae Won
    Jo, Sook Jung
    Lee, Jin Soo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (10) : 1122 - 1128
  • [7] Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
    Inoue, A.
    Kobayashi, K.
    Maemondo, M.
    Sugawara, S.
    Oizumi, S.
    Isobe, H.
    Gemma, A.
    Harada, M.
    Yoshizawa, H.
    Kinoshita, I.
    Fujita, Y.
    Okinaga, S.
    Hirano, H.
    Yoshimori, K.
    Harada, T.
    Saijo, Y.
    Hagiwara, K.
    Morita, S.
    Nukiwa, T.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (01) : 54 - 59
  • [8] Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)
    Kobayashi, Kunihiko
    Hagiwara, Koichi
    [J]. TARGETED ONCOLOGY, 2013, 8 (01) : 27 - 33
  • [9] CORRECTING OVERALL SURVIVAL FOR THE IMPACT OF CROSSOVER VIA A RANK-PRESERVING STRUCTURAL FAILURE TIME (RPSFT) MODEL IN THE RECORD-1 TRIAL OF EVEROLIMUS IN METASTATIC RENAL-CELL CARCINOMA
    Korhonen, P.
    Zuber, E.
    Branson, M.
    Hollaender, N.
    Yateman, N.
    Katiskalahti, T.
    Lebwohl, D.
    Haas, T.
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2012, 22 (06) : 1258 - 1271
  • [10] Lack of prognostic value of EGFR mutations in primary resected non-small cell lung cancer
    Lim, Ken-Hong
    Huang, Ming-Jer
    Liu, Hung-Chang
    Kuo, Hsu-Tah
    Tzen, Chin-Yuan
    Hsieh, Ruey-Kuen
    [J]. MEDICAL ONCOLOGY, 2007, 24 (04) : 388 - 393
123